These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 25083925

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL, Perrone CE, Mattocks DA, Ables GP, Caliendo NS, Orentreich DS, Orentreich N.
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH, Chapman MJ, Kontush A.
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [Abstract] [Full Text] [Related]

  • 7. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
    Raposo HF, Patrício PR, Simões MC, Oliveira HC.
    J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
    [Abstract] [Full Text] [Related]

  • 8. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Sahebkar A, Chew GT, Watts GF.
    Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
    [Abstract] [Full Text] [Related]

  • 9. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.
    Toth PP.
    Vasc Health Risk Manag; 2016 Mar; 12():171-83. PubMed ID: 27226718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel therapeutics in hypertriglyceridemia.
    Gryn SE, Hegele RA.
    Curr Opin Lipidol; 2015 Dec; 26(6):484-91. PubMed ID: 26780002
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC, Duriez P.
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [Abstract] [Full Text] [Related]

  • 15. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D, Drouin-Chartier JP, Couture P.
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
    Quispe R, Sweeney T, Varma B, Agarwala A, Michos ED.
    Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
    [Abstract] [Full Text] [Related]

  • 18. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
    Ward NC, Chan DC, Watts GF.
    BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
    [Abstract] [Full Text] [Related]

  • 19. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
    Ooi EM, Barrett PH, Chan DC, Watts GF.
    Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.